Is anti-doping analysis so far from clinical, legal or forensic targets?: The added value of close relationships between related disciplines

被引:12
作者
Segura, Jordi [1 ,2 ]
机构
[1] IMIM Hosp Mar, Bioanal Res Grp, Barcelona 08003, Spain
[2] Univ Pompeu Fabra, Dept Expt & Hlth Sci, Barcelona, Spain
关键词
co-operation; related disciplines; clinical diagnostics; tumour marker; blood transfusion network; overlapping jurisdictions; deliberate team intoxication; sample tempering; publications; RECOMBINANT ERYTHROPOIETIN; URINE; PERFORMANCE; SUBSTANCES; HORMONE;
D O I
10.1002/dta.55
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
There are many areas of common interest between anti-doping laboratories and those working in the clinical, legal and forensic fields. In addition to methodological similarities, there are aspects of the findings in sport drug testing that overlap with other fields in such a way that sport drug testing and clinical, legal or forensic work may benefit from mutual interaction. Three recent examples are presented from the author's experience. Case report 1 concerns the clinical relevance of hCG findings in sport drug testing as potential indicators of the presence of a (testicular) tumour in athletes. Case report 2 refers to difficulties that accredited laboratories can encounter due to differences between national legal systems and the administrative regulation systems of sport authorities. The example involves a network of blood collection for further autologous transfusion. Case report 3 relates to additional forensic-type investigations needed to interpret a situation where intoxication of a whole delegation was responsible for apparent doping cases. Clinical, legal and forensic fields must recognize the added value that some results and developments coming from anti-doping laboratories may have. At the same time anti-doping analysts should be aware of new issues, methodologies and problems appearing in related fields. Copyright (C) 2009 John Wiley & Sons, Ltd.
引用
收藏
页码:479 / 484
页数:6
相关论文
共 28 条
[1]  
ALFTHAN H, 1992, CLIN CHEM, V38, P1981
[2]   Doping: similar problems arise in medical clinics [J].
Altschuler, Eric L. .
NATURE, 2008, 455 (7210) :167-167
[3]   Doping in the recombinant era: Strategies and counterstrategies [J].
Azzazy, HME ;
Mansour, MMH ;
Christenson, RH .
CLINICAL BIOCHEMISTRY, 2005, 38 (11) :959-965
[4]  
Beran Roy G, 2008, J Forensic Leg Med, V15, P158, DOI 10.1016/j.jflm.2007.08.003
[5]   New and old challenges of sports drug testing [J].
Botre, Francesco .
JOURNAL OF MASS SPECTROMETRY, 2008, 43 (07) :903-907
[6]  
Bowers LD, 1996, CLIN CHEM, V42, P999
[7]   New discoveries on the biology and detection of human chorionic gonadotropin [J].
Cole, Laurence A. .
REPRODUCTIVE BIOLOGY AND ENDOCRINOLOGY, 2009, 7
[8]   Cardiovascular toxicities of performance-enhancing substances in sports [J].
Dhar, R ;
Stout, CW ;
Link, MS ;
Homoud, MK ;
Weinstock, J ;
Estes, NAM .
MAYO CLINIC PROCEEDINGS, 2005, 80 (10) :1307-1315
[9]   Supraphysiological growth hormone:: less fat, more extracellular fluid but uncertain effects on muscles in healthy, active young adults [J].
Ehrnborg, C ;
Ellegård, L ;
Bosaeus, I ;
Bengtsson, BÅ ;
Rosén, T .
CLINICAL ENDOCRINOLOGY, 2005, 62 (04) :449-457
[10]   Clinical review: The rationale for banning human chorionic gonadotropin and estrogen blockers in sport [J].
Handelsman, DJ .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2006, 91 (05) :1646-1653